1 min read.Updated: 03 Dec 2019, 04:21 PM ISTLeroy Leo
Globally, rotavirus causes approximately 200,000 deaths and about 2 million hospitalizations annually, mostly in low-income countries
In India, the company plans to target private hospitals for supply of the vaccines, as well as export to countries in Africa and Asia
NEW DELHI :
Bharat Biotech International on Tuesday launched a new variant of its rotavirus vaccine, Rotavac 5D, a smaller dosage form of its earlier oral immunisation shot that can be stored at a relatively higher temperature.
Available in a 0.5 ml dosage, Rotavac 5D can be stored at 2-8 degree Celsius for up to 24 months, and can be administered in five drops. Rotavac 5D is also stable at 37 degree Celsius for seven days.
The company has around 60-70% market share for rotavirus vaccines in India, a company official said. Competitors to Bharat Biotech’s Rotavac are GlaxoSmithKline’s Rotarix, Merck’s RotaTeq and Serum Institute of India’s Rotasil.
The Bharat Biotech vaccine’s newer variant, Rotavac 5D, however, will not be part of the Indian immunization scheme as the Indian government has said it has enough storage at -20 degree Celsius and does not need vaccines at a relatively higher temperature as of now, the company’s chairman and managing director Krishna Ella said.
In India, the company plans to target private hospitals for supply of the vaccines, as well as export to countries in Africa and Asia.
For vaccines, it is important that they are stored at the right temperature as exposure to temperatures outside the specified range may result in reduced vaccine potency or increased risk of vaccine-preventable diseases. In the worst case, the vaccines can even cause diseases it is supposed to immunize against.
Globally, rotavirus causes approximately 200,000 deaths and about 2 million hospitalizations annually, mostly in low-income countries.